Zacks Sets $16 Target for Pagaya, Reinforcing Profits but Underlining Persistent Funding Risks

What happened

Zacks Investment Research recently issued a $16 price target for Pagaya Technologies, citing four consecutive profitable quarters and upbeat 2026 guidance, which aligns with the upper end of DeepValue's bull case. This external optimism contrasts with DeepValue's 'WAIT' rating, which emphasizes that Pagaya's near-term upside depends on converting strong asset-backed securities (ABS) access into positive unit economics, not just deal volume. The news acknowledges weak momentum and funding-cost sensitivity, mirroring DeepValue's concerns over negative capital markets execution fees and recent credit reserve builds that threaten profitability. Despite the upbeat guidance, Pagaya's model remains vulnerable to spread shocks, as evidenced by a one-time allowance addition of 112,263 and ending balance of (252,934) in the latest filings. Therefore, while the target highlights growth potential, the critical view stresses that investor returns hinge on observable proof of improved execution fees and stable credit reserves within the next 3-6 months.

Implication

The $16 price target from Zacks suggests potential upside, but it may overstate near-term durability given Pagaya's historical vulnerability to ABS market volatility and negative execution fees. Pagaya's guidance is ambitious, yet the company's concentrated funding sources and 5% risk retention requirement expose it to rapid margin erosion if investor appetite cools or credit reserves increase further. Weak momentum signals fragile market sentiment, where any deterioration in ABS pricing or investor breadth could drive the stock toward DeepValue's bear case of $7, underscoring the lack of margin of safety. DeepValue's 'WAIT' rating remains prudent, advocating for monitoring upcoming quarterly filings for signs of stabilized credit reserves and a return to positive capital markets execution fees as key catalysts. Ultimately, investors should prioritize risk management, considering entry points around $10 as more attractive, and avoid aggressive positioning until the next ABS prints and financial disclosures confirm durable profitability.

Thesis delta

The news does not materially shift the investment thesis; it reinforces the existing narrative that Pagaya's profitability is real but precarious due to funding-cost sensitivity and credit risks. However, it introduces external validation of the bull case, suggesting that if Pagaya sustains its guidance and mitigates these risks, the stock could re-rate toward $16, aligning with DeepValue's base-to-bull range. This underscores the need for vigilance on upcoming ABS prints and financial reports to verify whether execution fees turn positive and credit reserves stabilize, as these are the primary drivers of any thesis upgrade.